Literature DB >> 4317857

Studies on the interrelationship between the syntheses of noradrenaline and metaraminol.

G E Johnson, T A Pugsley.   

Abstract

1. Experiments were conducted to determine the influence of the rate of noradrenaline synthesis on the conversion of alpha-methyl-m-tyrosine to metaraminol.2. Male Wistar rats, 175-200 g, were placed into four groups and treated with (1) alpha-methyl-p-tyrosine methyl ester, 250 mg/kg; (2) DL-alpha-methyl-m-tyrosine, 400 mg/kg; (3) alpha-methyl-p-tyrosine methyl ester, 250 mg/kg plus DL-alpha-methyl-m-tyrosine, 400 mg/kg; or (4) an equivalent volume of injection vehicle. All solutions were injected intraperitoneally.3. Immediately after treatment half of the rats were transferred to 4 degrees C with the remaining animals being kept at 27 degrees C.4. The rats were killed 4, 8 and 12 h after injection, the brains, hearts, spleens and adrenals removed and analysed for adrenaline, noradrenaline, metaraminol and alpha-methyl-m-tyramine.5. In virtually all cases, both during rest (27 degrees C) and sympathetic stress (4 degrees C), treatment of the rats with alpha-methyl-p-tyrosine methyl ester increased the amount of metaraminol formed from alpha-methyl-m-tyrosine. The only organ not containing increased quantities of metaraminol in the presence of alpha-methyl-p-tyrosine methyl ester was the adrenals, taken from the rats kept at 27 degrees C. Adrenals removed from the cold-exposed rats contained more metaraminol when alpha-methyl-p-tyrosine methyl ester was combined with alpha-methyl-m-tyrosine than when alpha-methyl-m-tyrosine was used alone.6. These results demonstrate that the inhibition of noradrenaline synthesis, by treatment with the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine methyl ester, increased the conversion of alpha-methyl-m-tyrosine to metaraminol. It is concluded that inhibiting the formation of dopa allowed increased amounts of alpha-methyl-m-tyrosine to enter the biosynthetic pathway. These results support the false sympathetic transmitter concept advanced for metaraminol.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4317857      PMCID: PMC1702959          DOI: 10.1111/j.1476-5381.1970.tb09566.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  In-vivo decarboxylation of alpha-methyl DOPA and alpha-methyl metatyrosine.

Authors:  A CARLSSON; M LINDQVIST
Journal:  Acta Physiol Scand       Date:  1962-01

2.  Improved technique for the fluorimetric estimation of catecholamines.

Authors:  U von EULER; F LISHAJKO
Journal:  Acta Physiol Scand       Date:  1961-04

Review 3.  False adrenergic transmitters.

Authors:  I J Kopin
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

4.  Modified method for the estimation of metaraminol and alpha-methyl-m-tyramine.

Authors:  T A Pugsley; G E Johnson
Journal:  J Pharm Pharmacol       Date:  1968-06       Impact factor: 3.765

5.  The influence of cold exposure on the in vivo release of metaraminol.

Authors:  G E Johnson; D Mickle
Journal:  Br J Pharmacol Chemother       Date:  1966-11

6.  Central effects of an inhibitor of tyrosine hydroxylation.

Authors:  H Corrodi; L C Hanson
Journal:  Psychopharmacologia       Date:  1966

7.  Acceleration of noradrenaline turnover in the mouse heart by cold exposure.

Authors:  A Oliverio; L Stjärne
Journal:  Life Sci       Date:  1965-12       Impact factor: 5.037

8.  The effect of nerve activity on the depletion of the adrenergic transmitter by inhibitors of noradrenaline synthesis.

Authors:  H Corrodi; T Malmfors
Journal:  Acta Physiol Scand       Date:  1966 Jul-Aug

9.  Regulation of metaraminol efflux from rat heart and salivary gland.

Authors:  E Costa; N H Neff; S H Ngai
Journal:  Br J Pharmacol       Date:  1969-05       Impact factor: 8.739

10.  The formation and release of metaraminol during exposure to warm or cold environments.

Authors:  G E Johnson; T A Pugsley
Journal:  Br J Pharmacol       Date:  1968-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.